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Wu et al S26.e2Background: Most melanoma studies use data from the National Cancer Institute Surveillance, Epidemi-
ology, and End Results Program or individual cancer registries. Small numbers of melanoma cases have
limited in-depth analyses for all racial and ethnic groups.Objective: We sought to describe racial and ethnic variations in melanoma incidence and survival.Methods: Incidence for invasive melanoma and 5-year melanoma-specific survival were calculated for
whites, blacks, American Indians/Alaskan Natives, Asians/Pacific Islanders (API), and Hispanics using data
from 38 population-based cancer registries.Results: Incidence rates of melanoma were significantly higher for females than males among whites and
Hispanics under 50 years of age and APIs under 40 years of age. White and black patients were older (median
age: 59-63 years) compared with Hispanics, American Indians/Alaskan Natives, and API (median age: 52-56
years). The most common histologic type was acral lentiginous melanoma among blacks and superficial
spreadingmelanomaamongall other racial andethnic groups.Hispanicshad thehighest incidence rate of acral
lentiginousmelanoma, significantly higher thanwhites andAPI.Nonwhitesweremore likely tohave advanced
and thicker melanomas at diagnosis and lower melanoma-specific survival compared with whites.Limitations: Over 50% of melanoma cases did not have specified histology. The numbers of nonwhite
patients were still relatively small despite broad population coverage (67% of United States).Conclusions: Racial and ethnic differences in age at melanoma diagnosis, anatomic sites, and histologic
types suggest variations in etiologic pathways. The high percentages of advanced and thicker melanomas
among nonwhites highlight the need to improve melanoma awareness for all race and ethnicity in the
United States. ( J Am Acad Dermatol 2011;65:S26.e1-13.)
Key words: anatomic sites; cancer registry; histology; incidence; melanoma; race and ethnicity; survival.Invasive cutaneous melanoma is the fifth most predominantly among whites (95%), followed by
commonly diagnosed cancer among men and sev-
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S26.e3 Wu et alThe low incidence of cutaneous melanoma among
nonwhite populations is attributable primarily to the
protective effects of pigmented skin.4 People with
darker skin have a high melanin density, which
reduces the risk of cutaneous melanoma induced by
ultraviolet radiation from sun exposure.5 In addition
to the low risk of cutaneous melanoma amongCAPSULE SUMMARY
d Incidence rates of melanoma were
significantly higher for females than
males among whites and Hispanics
under 50 years of age and APIs under 40
years of age.
d White and black patients were older
(median age: 59-63 years) than those in
Hispanics and other racial groups
(median age: 52-56 years).
d The most common histology was acral
lentiginous melanoma among blacks
and superficial spreading melanoma
among others. Hispanics had the highest
incidence of acral lentiginous melanoma
among all races and ethnicities.
d Nonwhite patients were more likely to
have advanced and thicker melanoma at
diagnosis and lower survival compared
with whites.nonwhite racial and ethnic
groups, research has also
identified numerous racial
and ethnic differences in
melanoma incidence, partic-
ularly with regard to
anatomic distributions and
histologic types along with
variations in stage at diagno-
sis and survival.3-9
Most previous population-
based studies on melanoma
incidence and survival were
based on data from the
National Cancer Institute
(NCI) Surveillance, Epidemi-
ology, and End Results
(SEER) Program, which cov-
ered up to 26% of the US
population, or individual
population-based cancer
registries.3,6,7,10,11 Although
SEER registries cover diverse
populations, small numbers
of melanoma cases among
nonwhite populations have precluded in-depth anal-
yses for all racial and ethnic groups. Combined data
from registries supported by the Centers for Disease
Control and Prevention (CDC) National Program of
Cancer Registries (NPCR) and the NCI SEER Program
provided an opportunity to study melanoma inci-
dence and survival including detailed examination of
racial and ethnic variations.
The purpose of this studywas to describe race and
ethnicity variations in melanoma incidence and
survival.
METHODS
Data source
This study used two data sets. Cancer incidence
and stage analyses were based on the 1999 to 2006
data, covering approximately 67% of the US popu-
lation, from 38 population-based cancer registries
that were the participants of the CDC NPCR, NCI
SEER Program, or both.12 Both the NPCR and SEER
registries use the data standards compiled by the
North American Association of Central Cancer
Registries (NAACCR).13 Data met high-qualitystandards for inclusion in the United States
Cancer Statistics publication.1 Survival analyses
were based on 1999 to 2005 data from 17 SEER
registries covering approximately 26% of the US
population.2
Information on race and ethnicity in the two data
sets were obtained originally from medical records,and enhanced by the
NAACCR Hispanic Identifi-
cation Algorithm and by link-
ages with Indian Health
Services patient registration
data set.14,15 The purpose of
the enhancements was to rec-
tify misclassifications and im-
prove identifications of
Hispanic and AI/AN cases.14
The racial and ethnic groups
included in this report were
all whites (whites), Hispanic
whites, non-Hispanic whites,
Hispanics regardless of race,
blacks, AI/AN, and API.
Racial groups (whites,
blacks, AI/AN, and API)
included all cases in the
race-specific categories irre-
spective of Hispanic status.
Therefore, racial and ethnic
groups were not mutually
exclusive. Approximately
4% of the melanoma cases(11,779) had no specified race information. These
cases were not included in the race-specific anal-
ysis. For the sake of simplicity, we focused the
results and discussion on whites, blacks, AI/AN,
API, and Hispanics.
Analyses were limited to invasive, microscopically
confirmed melanoma cases. There were 0.9% of the
cases without microscopic confirmation. Melanoma
cases were categorized into the following anatomic
groups: head and neck (C44.0-C44.4), upper limb
and shoulder (C44.6), trunk (C44.5), lower limb and
hip (C44.7), overlapping lesions (C44.8), andunknown
(C44.9). Histologic types were grouped as superficial
spreading melanoma (SSM) (Morphology(M)8743),
lentigo maligna melanoma (LMM) (M8742), acral
lentiginous melanoma (ALM) (M8744), nodular mela-
noma (M8721), desmoplastic melanoma (M8745),
amelanotic melanoma (M8730), other specific mela-
nomas (M8722-M8727, M8740-M8741, M8761-8774),
and melanoma not otherwise specified (M8720).
Three staging systems were used for melanoma
cases diagnosed in years 1999 to 2006. The cases
diagnosed in 1999 to 2000 were staged according to
Abbreviations used:
AI/AN: American Indians/Alaskan Natives
ALM: acral lentiginous melanoma
API: Asians/Pacific Islanders
CDC: Centers for Disease Control and
Prevention
LMM: lentigo maligna melanoma
NCI: National Cancer Institute
NPCR: National Program of Cancer Registries
SEER: Surveillance, Epidemiology, and End
Results
SSM: superficial spreading melanoma
SS2000: SEER Summary Stage Manual-2000
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nosed in 2001 to 2003 were staged using the 2001
SEER Summary Stage Manual (SS2000), and those
diagnosed in 2004 and after were staged according
the Collaborative Staging Manual, which were con-
verted to the derived SS2000. Stage distributions
based on the 3 staging systems were not entirely
comparable for cutaneous melanoma. A shift from
local to regional stage was observed from 1977
SEER Summary Stage to SS2000 and from directly
coded SS2000 to Collaborative Staging derived
SS2000. Because the overall scales of the stage shift
were fairly small, the 1999 to 2006 cases were
combined in this report. Data on melanoma thick-
ness were from the 17 SEER registries as NPCR
registries do not consistently collect and report the
data.
For survival analyses, only cases that were not
diagnosed using death certificate or autopsy were
included. To eliminate possible impact of previous
and subsequent cancers on survival time, we only
included patients with melanoma as the first and
only primary cancer (excluded about 11% of the
cases with multiple primary cancers). SEER historic
stage was used in the survival analysis because the
definitions of SEER historic stage remained the
same over time and there were no incomparability
issues with this stage. As standard life tables were
not available for AI/AN, API, and Hispanic popula-
tions, melanoma-specific survival was chosen to
eliminate impacts of other comorbidities on survival
rates. Approximately, 0.3% of the melanoma cases
eligible for survival analysis were excluded due to
the lack of information on cause of death. The
cutoff date for vital status follow-up was December
31, 2006.
Statistical analysis
Frequencies, percent distributions, and incidence
rates were computed by age group, sex, anatomic
site, and histologic type for all racial and ethnicgroups. Rates and 95% confidence interval were
presented per 100,000 persons age-adjusted to the
2000 US population standard.16 In describing rate
comparisons, the term ‘‘higher’’ or ‘‘lower’’ was used
when the rate ratio differed significantly from 1.0
(P\ .05) unless otherwise specified. To remove the
effects of differences in age on stage distribution,
relative percentages were calculated as the rate for a
particular stage or tumor thickness group divided by
the rate for all stages or all tumor thickness groups;
the latter equals the sum of overall individual
stages or thickness groups of the rate. Five-year
melanoma-specific survival was calculated using
Kaplan-Meier method. Values based on fewer than
16 cases were suppressed except those used for
graphs. All data analyses were performed using the
SEER*Stat software, 6.6.1 (Information Management
Services, Inc, Silver Spring, MD, http://seer.cancer.
gov/seerstat/).RESULTS
A total of 288,741 invasive melanoma cases were
reported in the study area during years 1999 to 2006;
the average annual incidence rate was 18.3 per
100,000 for all races and sexes combined. Overall
incidence rate increased by 2.4% per year (P\ .05)
during the period. Whites, blacks, AI/AN, and API
comprised 95%, 0.5%, 0.2%, and 0.3% of the cases,
respectively. There were 5613 melanoma cases
among Hispanics (2%), regardless of race (Table I).
Approximately 4% of the cases had no information
on race (data not shown). The median age varied by
race and ethnicity from 52 years for Hispanics to 63
years for blacks.Demographic and clinical characteristics by
race and ethnicity
Overall, Hispanic, AI/AN, and API patients with
melanoma were younger at diagnosis than their
white and black counterparts; the former had a
higher percentage for the younger age groups but
the latter had a higher percentage for the old age
groups (Table I). The majority of cases among whites
and AI/AN were male, whereas among blacks, API,
and Hispanics more cases were female.
The trunk was the predominant site among
whites and AI/AN, whereas the lower limb and
hip was the most common site among blacks and
API. Among Hispanics, the percentage the trunk
was about the same as that of lower limb and hip.
With the exception of blacks for whom ALM was the
most common type, SSM was the most common
histologic type among all racial and ethnic groups
(Table I).
Table I. Demographic and clinical characteristics of invasive melanomas by race and ethnicity in the United
States, 1999 to 2006
Whites*
Blacks* AI/AN* API* Whites* Non-Hispanics Hispanics Hispanics*,y
Characteristics Count % Count % Count % Count % Count % Count % Count %
Median age, y 63 54 56 59 60 52 52
All invasive melanoma 1396 100.0 567 100.0 947 100.0 274,052 100.0 268,712 100.0 5340 100.0 5613 100.0
Age at diagnosis, y
\40 221 15.8 130 22.9 197 20.8 39,247 14.3 37,957 14.1 1290 24.2 1372 24.4
40-49 166 11.9 104 18.3 165 17.4 44,560 16.3 43,458 16.2 1102 20.6 1155 20.6
50-64 341 24.4 171 30.2 239 25.2 78,354 28.6 77,014 28.7 1340 25.1 1404 25.0
65-74 295 21.1 84 14.8 159 16.8 52,142 19.0 51,304 19.1 838 15.7 873 15.6
$ 75 373 26.7 78 13.8 187 19.7 59,749 21.8 58,979 21.9 770 14.4 809 14.4
Sex
Male 620 44.4 292 51.5 457 48.3 155,752 56.8 153,426 57.1 2326 43.6 2431 43.3
Female 776 55.6 275 48.5 490 51.7 118,300 43.2 115,286 42.9 3014 56.4 3182 56.7
Anatomic site
Head and neck (C44.0-C44.4) 147 10.5 108 19.0 128 13.5 56,013 20.4 55,040 20.5 973 18.2 1017 18.1
Upper limb and shoulder
(C44.6)
180 12.9 133 23.5 170 18.0 66,059 24.1 64,941 24.2 1118 20.9 1184 21.1
Trunk (C44.5) 225 16.1 159 28.0 228 24.1 90,081 32.9 88,665 33.0 1416 26.5 1497 26.7
Lower limb and hip (C44.7) 677 48.5 124 21.9 338 35.7 49,054 17.9 47,572 17.7 1482 27.8 1556 27.7
Overlapping lesions (C44.8) x x x x x x 376 0.1 374 0.1 x x x x
Unknown (C44.9) 164 11.7 42 7.4 83 8.8 12,469 4.5 12,120 4.5 349 6.5 357 6.4
Histology
Superficial spreading
(M8743)
168 12.0 142 25.0 211 22.3 78,354 28.6 77,037 28.7 1317 24.7 1388 24.7
Lentigo maligna (M8742) 39 2.8 24 4.2 30 3.2 16,393 6.0 16,252 6.0 141 2.6 151 2.7
Acral lentiginous (M8744) 216 15.5 x x 69 7.3 2316 0.8 2100 0.8 216 4.0 223 4.0
Nodular (M8721) 92 6.6 44 7.8 89 9.4 19,191 7.0 18,721 7.0 470 8.8 484 8.6
Desmoplastic (M8745) 19 1.4 x x x x 3192 1.2 3137 1.2 55 1.0 56 1.0
Amelanotic (M8730) x x x x x x 1260 0.5 1231 0.5 29 0.5 29 0.5
Other specific melanomaz 64 4.6 21 3.7 38 4.0 8463 3.1 8248 3.1 215 4.0 220 3.9
Melanoma NOS (M8720) 797 57.1 316 55.7 493 52.1 144,883 52.9 141,986 52.8 2897 54.3 3062 54.6
Data are from 38 population-based cancer registries that participate in National Program of Cancer Registries and/or Surveillance,
Epidemiology, and End Results Program and meet high-quality data criteria.14 These registries cover 67% US population for 1999 to 2006.
AI/AN, Non-Hispanic American Indian/Alaska Native; API, Asian/Pacific Islander; NOS, not otherwise specified.
*Hispanic ethnicity is not mutually exclusive from race. Whites included both non-Hispanic whites and Hispanic whites.
yInclude all Hispanic regardless of race.
zM8722-M8727, M8740-M8741, M8761-8774.
xStatistic not displayed because fewer than 16 cases in this category.
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anatomic site, and histology
Whites had the highest age-adjusted rates of
melanoma followed by Hispanics, AI/AN, API, and
blacks (Table II). Rates increased steadily with age
for all racial and ethnic groups. Rates were higher for
males than for females among whites, AI/AN, and
API and similar by sex among Hispanics and blacks.
Females younger than 50 years had a higher rate than
their male counterparts for all racial and ethnic
groups although the differences were statistically
significant only for whites and Hispanics and API
younger than 40 years (Figs 1 and 2). Among older
age groups, rates were higher for males than for
females.Rates of melanoma for the trunk were higher than
those of other sites among whites, whereas among
blacks and API, the rates for lower limb and hip were
higher (Table II). The rates of SSM were much higher
among whites than among other racial and ethnic
groups; rate ratios varied substantially by race and
ethnicity. For ALM, the rate for Hispanics was not
significantly different from that of blacks but higher
than the rates of whites and API. API had a signifi-
cantly lower rate of ALM than all racial and ethnic
groups with 16 or more cases. Whites had the highest
rate of nodular melanoma followed by Hispanics, AI/
AN, API, and blacks. Rates of nodular melanoma
among blackswere lower than those of all other racial
and ethnic groups.
Table II. Race- and ethnicity-specific incidence rates of invasive melanoma by age, sex, anatomic site, and histology in United States, 1999 to 2006 (age-
adjusted to the 2000 US population standard)
Whites*
Blacks* AI/AN* API* Whites* Non-Hispanics Hispanics Hispanics*,y
Characteristics Rate 95% CI Rate 95% CI Rate 95% CI Rate 95% CI Rate 95% CI Rate 95% CI Rate 95% CI
All invasive melanoma 1.04 (0.98-1.09) 4.52 (4.13-4.94) 1.46 (1.36-1.55) 20.30 (20.23-20.38) 21.93 (21.85-22.02) 4.73 (4.59-4.87) 4.68 (4.55-4.82)
Age at diagnosis, y
\40 0.20 (0.17-0.23) 1.23 (1.03-1.46) 0.38 (0.33-0.44) 5.65 (5.60-5.71) 6.66 (6.60-6.73) 1.01 (0.99-1.10) 1.04 (0.98-1.09)
40-49 0.62 (0.53-0.73) 4.15 (3.39-5.03) 1.40 (1.20-1.63) 22.47 (22.26-22.68) 24.67 (24.44-24.91) 4.99 (4.70-5.29) 4.88 (4.60-5.17)
50-64 1.48 (1.33-1.65) 7.81 (6.68-9.07) 2.19 (1.92-2.48) 36.65 (36.39-36.91) 39.08 (38.81-39.36) 8.03 (7.60-8.47) 7.91 (7.50-8.33)
65-74 3.67 (3.26-4.11) 13.19 (10.51-16.36) 4.16 (3.54-4.86) 59.69 (59.18-60.21) 62.80 (62.26-63.35) 14.88 (13.89-15.93) 14.73 (13.77-15.74)
$ 75 6.01 (5.41-6.65) 18.89 (14.93-23.58) 6.94 (5.98-8.01) 69.34 (68.79-69.90) 71.76 (71.18-72.34) 19.53 (18.17-20.96) 19.60 (18.27-21.00)
Sex
Male 1.14 (1.04-1.24) 5.20 (4.56-5.90) 1.65 (1.49-1.81) 25.15 (25.02-25.28) 27.02 (26.88-27.15) 4.92 (4.70-5.15) 4.86 (4.65-5.08)
Female 0.99 (0.92-1.06) 3.99 (3.51-4.51) 1.33 (1.21-1.46) 16.91 (16.81-17.01) 18.34 (18.24-18.45) 4.79 (4.61-4.97) 4.76 (4.58-4.93)
Anatomic site
Head and neck (C44.0-C44.4) 0.11 (0.09-0.13) 1.02 (0.82-1.24) 0.21 (0.17-0.25) 4.08 (4.04-4.11) 4.34 (4.30-4.38) 0.99 (0.92-1.05) 0.97 (0.91-1.04)
Upper limb and shoulder
(C44.6)
0.13 (0.11-0.15) 1.07 (0.88-1.28) 0.26 (0.22-0.31) 4.88 (4.88-4.84) 5.27 (5.22-5.31) 0.97 (0.91-1.03) 0.97 (0.91-1.03)
Trunk (C44.5) 0.15 (0.13-0.18) 1.13 (0.95-1.33) 0.33 (0.29-0.38) 6.73 (6.73-6.68) 7.35 (7.30-7.40) 1.16 (1.10-1.23) 1.15 (1.09-1.21)
Lower limb and hip (C44.7) 0.52 (0.48-0.56) 0.93 (0.76-1.12) 0.52 (0.46-0.58) 3.68 (3.68-3.65) 3.98 (3.94-4.02) 1.28 (1.21-1.35) 1.27 (1.20-1.34)
Overlapping lesions (C44.8) x x x x x x 0.03 (0.03-0.03) 0.03 (0.03-0.03) x x x x
Unknown (C44.9) 0.12 (0.10-0.14) 0.37 (0.26-0.51) 0.13 (0.11-0.17) 0.91 (0.90-0.93) 0.97 (0.95-0.99) 0.33 (0.30-0.37) 0.32 (0.29-0.36)
Histology
Superficial spreading
(M8743)
0.12 (0.10-0.14) 1.05 (0.88-1.25) 0.30 (0.26-0.34) 5.68 (5.82-5.90) 6.41 (6.36-6.45) 1.06 (1.00-1.12) 1.05 (0.99-1.11)
Lentigo maligna (M8742) 0.03 (0.02-0.04) 0.26 (0.16-0.39) 0.05 (0.03-0.07) 1.18 (1.16-1.20) 1.25 (1.23-1.27) 0.17 (0.14-0.20) 0.17 (0.14-0.20)
Acral lentiginous (M8744) 0.17 (0.15-0.20) x x 0.11 (0.09-0.14) 0.17 (0.16-0.18) 0.17 (0.16-0.17) 0.22 (0.19-0.25) 0.21 (0.18-0.24)
Nodular (M8721) 0.07 (0.06-0.08) 0.34 (0.24-0.47) 0.14 (0.11-0.18) 1.41 (1.39-1.43) 1.50 (1.47-1.52) 0.46 (0.42-0.51) 0.45 (0.40-0.49)
Desmoplastic (M8745) 0.01 (0.01-0.02) x x x x 0.23 (0.22-0.24) 0.25 (0.24-0.26) 0.05 (0.04-0.06) 0.05 (0.03-0.06)
Amelanotic (M8730) x x x x x x 0.09 (0.09-0.10) 0.10 (0.09-0.10) 0.03 (0.02-0.05) 0.03 (0.02-0.04)
Other specific melanomaz 0.05 (0.04-0.06) 0.18 (0.11-0.28) 0.06 (0.04-0.08) 0.63 (0.61-0.64) 0.67 (0.65-0.68) 0.19 (0.16-0.22) 0.18 (0.16-0.21)
Melanoma NOS (M8720) 0.58 (0.54-0.63) 2.49 (2.20-2.80) 0.77 (0.70-0.84) 10.74 (10.68-10.79) 11.59 (11.53-11.66) 2.56 (2.46-2.66) 2.55 (2.45-2.65)
Data are from 38 population-based cancer registries that participate in National Program of Cancer Registries and/or Surveillance, Epidemiology and End Results Program and meet high-quality
data criteria.14 These registries cover 67% US population for 1999 to 2006.
AI/AN, American Indian/Alaska Native; API, Asian/Pacific Islander; CI, confidence interval; NOS, not otherwise specified.
*Hispanics were not mutually exclusive from race. Whites included both non-Hispanic whites and Hispanic whites.
yInclude all Hispanic cases regardless of race.
zM8722-M8727, M8740-M8741, M8761-8774.
xStatistic not displayed because fewer than 16 cases in this category.
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Fig 1. Age-adjusted (2000 US) incidence rates of invasive melanoma by race/ethnicity, sex, and
age group. Data were from 38 population-based cancer registries that participate in National
Program of Cancer Registries and/or Surveillance, Epidemiology, and End Results Program
and meet high-quality data criteria. These registries cover 67% US population for 1999 to 2006.
AI/AN, American Indian/Alaska Native; API, Asian/Pacific Islander.
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and tumor thickness
Approximately 80% of the melanoma cases among
whites were localized stage at diagnosis, which was
much higher than the percentages among other racial
and ethnic groups (Table III). Distant melanomas
comprised 4% of cases among whites, whereas the
percentages were much higher among other groups
(7%-13%). Thin melanomas (# 1.0 mm in thickness)
were the majority (63%) among whites, but less com-
mon among other racial and ethnic groups (38%-48%).
Over 11% of melanoma cases were thicker than 4 mm
for blacks, AI/AN, and API, which was much higher
than those of whites (5%) and Hispanics (8%).
Five-year melanoma-specific survival rates by
histology, stage, and tumor thickness
The 5-year melanoma-specific survival was the
highest amongwhites followed byHispanics, AI/AN,API, and blacks (Table IV). LMM and SSM were the
two histologic types with the highest 5-year survival
among all racial and ethnic groups. Nodular mela-
noma had the lowest 5-year survival and substantial
racial and ethnic variation from 50% among blacks to
72% among API.
The 5-year survival was similar for localized
melanoma among all racial and ethnic groups
except blacks, for which the rate was slightly but
significantly lower than those of whites. There
were no significantly differences in the 5-year
survival by racial and ethnic groups for regional
and distant stage melanomas. The 5-year survival
decreased with increasing tumor thickness across
all racial and ethnic groups. Within each tumor
thickness group, the survival was comparable
and not statistically significant by racial and
ethnic group except for melanoma less than or
equal to 1.0 mm in thickness for which the 5-year
Fig 2. Age-adjusted (2000 US) incidence rates of invasive
melanoma by race/ethnicity, sex, and age group. Data
were from 38 population-based cancer registries that
participate in National Program of Cancer Registries and/
or Surveillance, Epidemiology, and End Results Program
and meet high-quality data criteria. These registries cover
67% US population for 1999 to 2006. NHW, Non-Hispanic
white.
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and API.
DISCUSSION
In this study, we provided a detailed description of
cutaneous melanoma incidence and survival patterns
for all major racial and ethnic groups in the United
States. To our knowledge, this is the first study to
provide such detailed, descriptive analyses using data
from both SEER and NPCR registries covering two
thirdsof theUSpopulation.Comparedwith the 2001 to
2006 melanoma incidence rates of the 17 SEER areas,
rates from this large studywere lower forwhites; higher
for AI/AN; and similar for API, blacks, and Hispanics.2
Observed variations between 17 SEER areas and 38
registry areas may be attributable to differences in
ultraviolet exposure, socioeconomic status, and
completeness of melanoma ascertainment.17,18
This study not only confirmed the previous find-
ing that incidence rates of melanoma were higher forfemales than males among whites younger than 45
years,2 but for the first time to our knowledge
reported that similar patterns occurred among
Hispanics, API, AI/AN, and blacks. This phenome-
non may be attributable to several factors. One of
them is indoor tanning use. A report published by the
World Health Organization International Agency for
Research on Cancer in 2007 discloses that individuals
whose first tanning bed use occurred before age 35
years have a 75% increased risk of melanoma; also
those who ‘‘ever’’ used a tanning bad have a signif-
icantly increased risk of melanoma than those who
‘‘never’’ used.19 Despite public health warnings,
tanning bed use is growing in the US rapidly.20-22 It
was estimated that about 28 million residents in the
US use tanning facilities; 70% of them are white girls
and women aged 16 to 49 years.23 It is unclear if
indoor tanning or intentional ultraviolet exposure is
a significant factor for racial and ethnic groups
besides whites. Regarding the association of female
hormones with the development of malignant mel-
anoma among young women findings have been
contradictory. Some studies found that use of oral
contraceptive or hormonal replacement was associ-
ated with increased risk of melanoma, whereas other
studies did not.24-27
Our data showed that anatomic distribution of
melanoma varied by race and ethnicity. The trunk
was the most common site amongwhites and AI/AN,
whereas the lower limb and hip was the predomi-
nant site for blacks and API. The percentages of the
trunk and low limb and hip were similar among
Hispanics. These findings are consistent with the
information in the literature for whites, API, AI/AN,
and blacks.3,4,28,29 For Hispanics, however, one
study showed that the trunk was the most common
site4,29 and two other studies, one based on 1992 to
2002 data from 11 SEER areas and one based on 1993
to 2003 California Cancer Registry data, showed that
lower limb and hip was the most common site.3,29
Inconsistent finding may be related to variations in
compositions of Hispanic subgroups and classifica-
tion of Hispanics by geographic area.
Melanomas occurring at different anatomic sites
may have different etiologic pathways.30,31 Patients
with cutaneous head and neckmelanomawere older
than those with melanoma on other skin sites,
whereas patients with melanoma on the trunk were
younger at diagnosis.32 A meta-analysis, based on
information from 29 published articles and 24 inde-
pendent study groups, found that associations of
intermittent sun exposure, continuous sun exposure,
and sunburns were each higher for usually sun-
exposed anatomic sites than for occasionally sun-
exposed sites.30,33 Melanomas on the trunk, lower
Table III. Race- and ethnicity-specific incidence of invasive melanoma by stage and thickness in the United States, 1999 to 2006
Whites*
Blacks* AI/AN* API* Whites* Non-Hispanics Hispanics Hispanics*
Count Rate R% Count Rate R% Count Rate R% Count Rate R% Count Rate R% Count Rate R% Count Rate R%
Stage at diagnosisy,z 1396 1.0 100.0 567 4.5 100.0 947 1.5 100.0 274,023 20.3 100.0 268,683 21.9 100.0 5340 4.7 100.0 5613 4.7 100.0
Localized 778 0.6 55.8 392 3.0 67.0 645 1.0 67.6 219,018 16.3 80.0 215,131 17.6 80.3 3887 3.4 71.5 4097 3.4 71.6
Regional 231 0.2 16.3 86 0.7 16.2 148 0.2 15.9 23,181 1.7 8.4 22,517 1.8 8.3 664 0.6 12.7 679 0.6 12.4
Distant 171 0.1 12.5 40 0.4 7.7 95 0.2 10.3 10,364 0.8 3.7 10,031 0.8 3.6 333 0.3 6.8 341 0.3 6.6
Unknown 216 0.2 15.4 49 0.4 9.1 59 0.1 6.2 21,460 1.6 7.8 21,004 1.7 7.7 456 0.4 9.1 496 0.4 9.4
Tumor thickness, mmk 417 1.0 100.0 143 2.9 100.0 619 1.4 100.0 93,221 22.4 100.1 90,445 26.0 100.0 2776 4.5 100.0 2905 4.4 100.0
# 1.0 160 0.4 37.9 77 1.4 48.1 277 0.6 42.9 58,215 14.0 62.5 56,818 16.4 63.3 1397 2.1 47.2 1492 2.1 48.2
1.01-2.0 60 0.1 13.7 22 0.4 14.7 75 0.2 12.9 12,432 3.0 13.3 12,004 3.4 13.2 428 0.7 15.5 435 0.7 15.2
2.01-4.0 47 0.1 11.6 x x 10.5 72 0.2 11.4 7171 1.7 7.7 6887 1.9 7.4 284 0.5 11.2 289 0.5 10.9
[4.0 51 0.1 12.6 x x 11.2 72 0.2 12.1 4247 1.0 4.6 4035 1.1 4.3 212 0.4 8.5 217 0.4 8.4
Unknown 99 0.2 24.2 19 0.4 15.4 123 0.3 20.7 11,156 2.7 12.0 10,701 3.1 11.8 455 0.8 17.5 472 0.8 17.4
AI/AN, American Indian/Alaska Native; API, Asian/Pacific Islander; Rate, adjusted to 2000 US population standard; R%, relative percentage (rate for particular group divided by the rate for all stages or
all thickness).
*Hispanics were not mutually exclusive from race. Whites included both non-Hispanic whites and Hispanic whites.
yStage data are from 38 population-based cancer registries that participate in National Program of Cancer Registries and/or Surveillance, Epidemiology and End Results (SEER) Program and meet
high-quality data criteria.14 These registries cover 67% US population for 1999 to 2006.
zSEER Summary Stage.
xStatistic not displayed because fewer than 16 cases in this category.
k2000 to 2006 Data on tumor thickness are from 17 population-based cancer registries that participate in SEER Program.
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Table IV. Five-year melanoma-specific survival rates* by histology, stage, thickness, race, and ethnicity in United States, 1999 to 2005
Whitesy
Blacksy AI/ANy APIy Whitesy Non-Hispanics Hispanics Hispanicsy,z
Rate 95% CI Rate 95% CI Rate 95% CI Rate 95% CI Rate 95% CI Rate 95% CI Rate 95% CI
All melanoma 78.2 (71.8-83.2) 84.9 (75.3-91.0) 80.7 (75.6-84.8) 90.0 (89.7-90.3) 90.2 (89.9-90.4) 86.5 (84.6-88.3) 87.0 (85.1-88.6)
Histology type
Superficial spreading (M8743) 94.9 (81.2-98.7) 90.8 (67.7-97.6) 87.5 (75.9-93.8) 96.2 (95.9-96.6) 96.2 (95.9-96.6) 96.5 (94.2-97.9) 96.7 (94.4-98.0)
Lentigo maligna (M8742) - - - - - - 97.2 (96.4-97.9) 97.2 (96.3-97.9) - - - -
Acral lentiginous (M8744) 81.3 (62.1-91.4) - - 85.0 (64.5-94.2) 83.4 (79.1-86.8) 84.3 (79.7-87.9) 78.7 (65.4-87.4) 79.1 (66.0-87.6)
Nodular (M8721) 49.7 (24.4-70.8) - - 71.9 (53.4-84.0) 70.9 (69.1-72.7) 71.1 (69.3-72.9) 66.8 (56.9-74.9) 67.0 (57.1-75.1)
Desmoplastic (M8745) - - - - - - 83.6 (79.6-86.9) 83.2 (79.1-86.6) 95.2 (70.7-99.3) 95.5 (71.9-99.3)
Amelanotic (M8730) - - - - - - 73.7 (66.9-79.4) 74.5 (67.5-80.1) - - - -
Other specific melanomax 91.7 (53.9-98.8) - - 57.1 (29.1-77.6) 88.1 (86.2-89.7) 88.2 (86.3-89.8) 85.6 (72.1-92.9) 86.2 (73.2-93.2)
Melanoma NOS (M8720) 72.0 (62.1-79.8) 87.7 (74.6-94.3) 81.4 (74.3-86.8) 88.2 (87.8-88.7) 88.4 (87.9-88.8) 85.0 (82.2-87.4) 85.5 (82.8-87.8)
Stage at diagnosisk
Localized 91.4 (84.5-95.4) 96.4 (86.4-99.1) 95.3 (91.2-97.6) 96.7 (96.5-96.9) 96.7 (96.5-96.9) 97.3 (96.0-98.2) 97.3 (96.0-98.2)
Regional 59.8 (42.1-73.7) 62.3 (30.2-82.9) 65.5 (51.0-76.6) 67.7 (66.4-69.0) 67.9 (66.5-69.3) 63.9 (57.2-69.8) 63.9 (57.2-69.8)
Distant 42.0 (21.5-61.3) - - 27.5 (12.6-44.8) 18.3 (16.2-20.5) 17.9 (15.8-20.2) 23.7 (14.1-34.7) 23.7 (14.1-34.7)
Unknown 74.4 (44.9-89.7) - - - - 79.2 (77.0-81.3) 79.3 (77.0-81.4) 76.4 (60.8-86.5) 76.4 (60.8-86.5)
Tumor thickness, mm
# 1.0 89.2 (80.6-94.1) 93.9 (82.3-98.0) 92.0 (85.5-95.7) 96.4 (96.2-96.6) 96.4 (96.2-96.7) 94.9 (92.9-96.3) 95.2 (93.4-96.5)
1.01-2.0 88.8 (67.2-96.5) - - 96.3 (76.5-99.5) 90.0 (89.2-90.9) 90.0 (89.1-90.8) 92.1 (87.0-95.3) 92.2 (87.1-95.3)
2.01-4.0 71.0 (50.8-84.1) - - 73.2 (56.1-84.5) 75.2 (73.5-76.7) 75.0 (73.3-76.7) 77.7 (69.7-83.8) 78.2 (70.4-84.2)
[4.0 61.4 (29.8-82.2) - - 63.4 (41.8-78.8) 59.6 (57.0-62.1) 59.8 (57.2-62.4) 56.0 (45.1-65.6) 56.3 (45.4-65.9)
Unknown 64.8 (50.6-75.8) - - 61.6 (48.5-72.3) 76.1 (75.0-77.2) 76.2 (75.1-77.3) 73.9 (67.8-79.0) 74.1 (68.2-79.1)
Data are from 17 population-based cancer registries that participate in SEER Program (see method section).
AI/AN, American Indian/Alaska Native; API, Asian/Pacific Islander; CI, confidence interval; NOS, not otherwise specified; -, not enough intervals to produce rate or fewer than16 cases in this category.
*Invasive microscopically confirmed melanoma (one primary only). Death clearance and autopsy excluded. Rate based on follow-up of patients into 2006.
yHispanics were not mutually exclusive from race. Whites included both non-Hispanic whites and Hispanic whites.
zInclude all Hispanic cases regardless of race.
xM8722-M8727, M8740-M8741, M8761-8774.
kSurveillance, Epidemiology, and End Results (SEER) historic stage.
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S26.e11 Wu et allimbs, and other not sun-exposed skin areas aremore
strongly related to inherent susceptibility than upper
limb and head and neck, as characterized by high
mole counts, rather than environmental exposure.34
Our data showed that themost common histologic
type for melanoma with specified histology was SSM
among all racial and ethnic groups except blacks, for
whom ALM was most common. This confirms previ-
ous findings.3,4,6,35 A different pattern, however, was
observed by one study based on data from a single
medical center.36 That study found that LMMwas the
most common histologic type counting for 56% of
melanoma cases, whereas SSM ranked the second
(29% of the cases). The above study had a similar
percentage of SSM as this study, but its percentage
for melanoma not otherwise specified was only
9%, much lower than that of this study ([50%).
Our study found that ALM was the most common
histologic type among blacks and that Hispanics had
the highest incidence rate of ALM among all racial
and ethnic groups; significantly higher than whites,
blacks, and API. Although this histologic type was
more common among blacks, the rate for blacks was
similar to that of whites in this study. It has been
reported that over 90% blacks have nevus; the
majority of melanocytic nevi among blacks were
acral, which may be related to the high number of
ALM among blacks.37 A study conducted in Spain
suggests that ALM is more likely related to specific
cancer susceptibility but not related to sun exposure,
familial melanoma, or propensity to developing
nevi.38
Stage distributions of melanoma and tumor thick-
ness varied substantially by racial and ethnic groups in
this study. Tumor thickness and ulceration are the
most powerful predictors of survival for patients with
localized melanoma.39 One study reported that nod-
ular melanoma grew at 4 times (nearly .5mm/mo) the
rate of either SSM or LMM.29,40 Delay in diagnosis (ie,
the time between recognition of an abnormality and
diagnosis of melanoma) has been found to be asso-
ciatedwith the thickness ofnodularmelanomabutnot
with other histologic types in a large population-
based study.41 The lower survival among nonwhite
groups than whites in this study was mainly attribut-
able to an advanced stage and thicker tumors at
diagnosis amongnonwhites.3,8,42,43 Numerous factors
may be responsible for delay in melanoma diagnosis
including inadequate education onmelanoma aware-
ness, limited access or barriers to medical care, pos-
sible decreased suspicion by providers for melanoma
among nonwhite patients, occurrence of lesions in
less noticeable body sites such as the sole of the foot,
and presence of race- and ethnicity-specific genetic
alterations.28Several limitations of this study should be noted.
First, despite a large population-based data encom-
passing two thirds of the US population, numbers of
melanoma cases were still too small to perform all in-
depth analyses for certain racial and ethnic groups.
Some unusual patterns may be attributable to small
numbers such as the survival for distant melanoma
cases among blacks. Second, underreporting is still a
problem for cutaneous melanomas because many
melanomas are diagnosed and treated at dermatol-
ogy offices and may not be reported to central
cancer registries.44,45 Furthermore, over 50% of
melanoma cases analyzed in this study were not
histology specified. Racial and ethnic variations in
histologic distributions and histology-specific inci-
dence rates may not be accurate although findings
of this study are consistent with previous studies. In
addition, as we mentioned in the methods section,
the information on race and ethnicity in cancer
registry data sets were originally obtained from
medical records. Although cancer registries strive
to improve the accuracy of race and ethnicity,
misclassifications may still exist, especially for mel-
anoma cases from physician offices where the
information on race and ethnicity may not be
collected from patients. Previous studies suggest
that less misclassification of AI/AN for cancer cases
occurred from Indian Health Services in Contract
Health Service Delivery Area counties than in all
counties.14 Melanoma incidence rates for AI/AN
based on both Contract Health Service Delivery
Area and non-Contract Health Service Delivery Area
counties in this study may underestimate the rates
for AI/AN. Finally, stage distributions were based on
stages coded using different staging systems over
time. It was reported there were slight shifts from
one stage to another using different staging
systems.46
Despite these limitations, this study provides a
comprehensive description of variations of cutane-
ous melanoma incidence and survival by race and
ethnicity. These results may not only help tailored
strategies and targeted efforts in melanoma preven-
tion and control but also provide clinicians additional
information in the diagnosis and treatment of mela-
noma among patients of various race and ethnicity.
Incidence rate ofmelanoma continues to increase 4%
annually in the United States, which is driven mainly
by the rate in the white population.47 Although
cutaneous melanomas are rare among nonwhite
populations, they are often diagnosed at an advanced
stage, which leads to a poor prognosis. To reduce the
burden of this malignant disease, it is crucial to
improve melanoma awareness and promote preven-
tion by reducing exposure to modifiable risk factors
J AM ACAD DERMATOL
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Wu et al S26.e12such as sun exposure and use of tanning beds as well
as improving early recognition of malignant mela-
noma among all racial and ethnic groups.
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